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OBJECTIVE: The objective of this selective EBM review is to determine whether or not fecal 
microbiota transplantation improves disease severity in irritable bowel syndrome patients 
compared to placebo. 
STUDY DESIGN: A systematic review of three double-blind, randomized, placebo-controlled 
trials published since 2014. 
DATA SOURCES: Articles found using PubMed, Cochrane Library, AMED and CINAHL Plus 
and selected based on their relevance to the clinical question. All sources published in peer 
reviewed journals in English.  
OUTCOME(S) MEASURED: Disease severity of irritable bowel syndrome measured in all 
three studies using the IBS-severity scoring system (IBS-SSS). 
RESULTS: The primary endpoint evaluated in all studies was improvement in symptom 
severity at 3 months after intervention quantified using IBS-SSS. Halkjær et al3 found a decrease 
in IBS-SSS of 52.45 ± 97.72 in the FMT group and a decrease in IBS-SSS of 125.71 ± 90.85 in 
the placebo group (p=0.012). Johnsen et al1 found 65% of FMT recipients vs. 43% of placebo 
recipients showed a decrease in IBS-SSS of > 75 points at 3 months after intervention (p=0.049). 
Aroniadis et al5 found a decrease in IBS-SSS of 221 ± 105 in the FMT group and a decrease of 
236 ± 64 in the placebo group (p=0.65). 
CONCLUSIONS:  Johnsen et al1 was the only study to demonstrate a statistically significant 
difference between the two groups in favor of FMT over placebo. Halkjær et al3 and Aroniadis et 
al5 reported a decrease in symptoms among both FMT and placebo groups with Halkjær et al3 
finding a statistically significant difference in favor of placebo while Aroniadis et al5 finding no 
statistical significance between the two groups. These 3 studies show conflicting evidence for the 
use of FMT in IBS patients although overall it does not appear FMT improves disease severity in 
IBS patients enough to justify the risk associated with FMT for a non-lethal disease.  
KEY WORDS: Fecal microbiota transplant, fecal transplant, and irritable bowel syndrome. 
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INTRODUCTION  
Irritable bowel syndrome (IBS) is a gastrointestinal disorder characterized by abdominal 
pain associated with changes in frequency or consistency of bowel movements thought to be due 
in part, to dysbiosis of the gut flora.1 It can be further categorized into diarrhea-predominant, 
constipation-predominant, or mixed subtypes and is considered a functional gastrointestinal (GI) 
disorder that lacks biochemical markers and relies on the Rome III criteria for diagnosis.2 It is 
the most commonly diagnosed GI condition affecting 1 in 5 people during their lifetime and 
greatly affects these patient’s quality of life.3  
It also carries a significant healthcare burden with IBS patients attending between 8.6-9.0 
visits with a healthcare provider annually compared to their counterparts without the disease who 
only attend 4.6 visits per year.2 These patients also have more emergency room visits and 
hospitalizations and receive twice as many hysterectomies and three times as many 
cholecystectomies.2 In the US, the annual cost per patient with IBS is estimated to be between 
$742 and $7,547 with a projected total cost of 1.4 billion dollars nationally.4 Furthermore, it is 
estimated that the total cost of IBS is comparable to the cost of other highly prevalent chronic 
illnesses such as hypertension, heart failure, migraines, and asthma,2 making this an area of 
interest to save in healthcare costs if a reliable treatment could be established.  
Additionally, of those with IBS who seek medical care, 90% of consultations are with a 
general practitioner,2 allowing physician assistants to play a large role in managing their care. 
Usually, IBS treatment begins with reassurance paired with lifestyle and dietary modifications to 
control symptoms.2 Pharmacologic treatment is typically limited to antispasmodics for 
abdominal pain and either laxatives for constipation-predominant symptoms or antidiarrheals for 
diarrhea-predominant symptoms.2 IBS has historically been considered a diagnosis of exclusion 
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and treated symptomatically, however, much is still unknown about the etiology of IBS and 
better understanding of the pathophysiology of IBS may offer room for new treatments to be 
explored. 
 It is currently thought that the microbiota in the GI tract may play a significant role in the 
etiology of IBS as those with the disease have shown significantly different gut microbiomes 
than healthy individuals.3 It has been demonstrated that treatments that target the gut flora such 
as probiotics, prebiotics, and antibiotics improve IBS disease severity,5 but whether or not other 
microbiome altering treatments, such as fecal microbiota transplantation (FMT) could offer relief 
for these patients has not yet been fully explored. FMT is a procedure where healthy donor stool 
is infused into a patient with dysbiosis of their gut flora either through endoscope, nasoenteric 
tube or oral capsules to establish new healthy gut microbiota.6 When considering other disease 
states that alter gut microflora, such as C. difficile infections, FMT has been more successful in 
eradicating the infection than standard therapies.3 Its success is thought be due to restoring 
healthy gut microbiota, suggesting this method may offer possible benefit to those with IBS as 
well.3 This paper evaluates three double blind randomized controlled trials comparing the 
efficacy of FMT on IBS disease severity compared to placebo. 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not fecal 
microbiota transplantation improves disease severity in irritable bowel syndrome patients 
compared to placebo. 
METHODS:  
Three double-blind, randomized, placebo-controlled trials were chosen for review.  
Articles were selected for review based on searches using the key words “fecal microbiota 
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transplant”, “fecal transplant”, and “irritable bowel syndrome” using PubMed, Cochrane Library, 
AMED and CINAHL Plus. Articles were selected based on their relevance to the clinical 
question, if they addressed patient oriented outcomes (POEMs), and if they met the inclusion and 
exclusion criteria. Inclusion criteria included randomized controlled trials (RCT) published since 
January 2014 and exclusion criteria included all studies published prior to January 2014 and 
those that were not RCTs. Each article was published in a peer reviewed journal in the English 
language. The statistics reported and used in this systematic review were p-values and mean 
change from baseline. Table 1 below provides more detail on the demographics and 
characteristics of the three studies chosen for review.  
The population being studied in this review is adults 18-75 years old diagnosed with IBS 
according to Rome III criteria with an IBS-severity scoring system (IBS-SSS) ≥ 175. The 
intervention in each study was FMT and comparison used was placebo. Authors Halkjær et al3 
and Aroniadis et al5 delivered FMT via oral capsules and used placebo capsules as comparison. 
Author Johnsen et al1 delivered FMT via colonoscope and used patients own feces as 
comparison. Outcomes obtained in all 3 studies were IBS disease severity as measured by IBS-
SSS. 
OUTCOMES MEASURED:  
Outcomes were measured via the IBS-severity scoring system (IBS-SSS). This is a self-
assessment questionnaire that evaluates the intensity of patient’s abdominal pain, distention, 
stool frequency and consistency, and interference in daily activities.1 Each of those five items is 
scored on a visual analog scale from 0-100 and then summed for a total score of 0-500.3 Scores 
between 175-300 indicate moderate disease severity and scores over 300 indicate severe 
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disease.1 Study participants in each RCT completed the questionnaire before, during and after 
receiving the intervention.  
Table 1 - Demographics & characteristics of included studies 
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Halkjær et al3 conducted a six month randomized, double-blind, placebo-controlled study 
of 52 adults with moderate to severe IBS based on inclusion/exclusion criteria presented in Table 
1 above. The participants were randomized into two demographically comparable groups of 26.3 
At 3 months, the FMT group had 1 patient lost to follow up and 1 excluded from analysis due to 
antibiotic treatment and the placebo group had 1 excluded from analysis due to probiotic 
treatment.3 The group receiving the intervention was instructed to orally ingest 25 capsules of 
mixed donor FMT each morning before eating for 12 consecutive days.3 Each daily dosage of 
FMT contained approximately 12g of fecal matter for a total of 144g of FMT ingested.3 The 
control group also followed this protocol but consumed capsules made of glycerol, saline and 
food coloring E150.3 
Participants were surveyed using the IBS-SSS and fecal samples collected at baseline, 1, 
3 and 6 months.3 The primary endpoint evaluated was mean change from baseline at 3 months in 
the two groups as to keep interpretation of outcomes the same among the three studies. Those 
receiving FMT had a decrease in their IBS-SSS of 52.45 ± 97.72 and those receiving placebo had 
a decrease of 125.71 ± 90.85 resulting in a statistically significant improvement in symptom 
severity among the placebo group (p=0.012) as seen in Table 2.3  
Twenty-two patients in the FMT group (84.6%) and 15 in the placebo group (57.7%) 
experienced adverse effects during the study although no side effects were more predominant in 
the FMT group compared to placebo except diarrhea (p=0.03).3 A complete list of adverse 
effects can be found in Table 3 below.
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Table 2 – Mean (SD) change in IBS-SSS from baseline to 3 months and statistical 
significance data from Halkjær et al3 








FMT group 341.68 (95.02) 287.14 (118.30) 52.45 (97.72) 
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 Placebo group 345.04 (79.56) 218.96 (121.87) 125.71 (90.85) 
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Johnsen et al1 conducted a double-blind, randomized, placebo controlled study of 90 
participants and randomized them into 3 groups of 30 based on inclusion/exclusion criteria 
presented in Table 1. One group received fresh FMT, one received frozen FMT and one received 
placebo.1 Two participants were lost to follow up in both the fresh FMT and placebo groups.1 In 
this study, 50-80g of either fresh or frozen donor feces or the patient’s own feces serving as 
placebo was mixed with saline and glycerol delivered via colonoscope to the cecum.1 
Loperamide 8mg was administered to both groups 2 hours prior in order to retain the transplant.1 
The primary endpoint evaluated was symptom relief of more than 75 points as assessed via IBS-
SSS from baseline to 3 months after intervention.1 Participants completed the IBS-SSS at 
baseline, 1, 3, 6, and 12 months after intervention.1 Analysis revealed 65% of FMT recipients vs. 
43% of placebo recipients showed a decrease in IBS-SSS of > 75 points at 3 months after 
intervention (p=.049).1
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Further analysis revealed those who received frozen FMT had a larger change in IBS-SSS from 
baseline than fresh FMT as demonstrated in Table 4 below.1 One serious adverse event occurred 
with a patient requiring hospital admission for observation after experiencing nausea and vertigo 
post transplant.1 Otherwise, mild adverse events are reported in Table 5 below. 
Table 4 – Mean change in IBS-SSS from baseline to 3 months and statistical significance 
data from Johnsen et al1 








Fresh FMT 260 150 110  
    .049 
 
Frozen FMT 280 155 125 
Placebo 278 250 28 
 
Table 5 – Adverse events from Johnsen et al1 
 FMT Placebo  
Soiling of transplant 1 (.02%) 1 (.03) 
Abdominal pain 1 (.02%) 2 (.07%) 
Nausea and vertigo 1 (.02%) 0 
 
Aroniadis et al5 conducted a 6 month double blind, randomized, placebo controlled trial 
that featured a crossover design. Twenty-five patients were assigned to receive FMT first and 23 
were assigned to receive placebo first.5 Three participants in the FMT first group were lost to 
follow up before 3 months and were excluded from analysis while none were lost to follow up in 
the placebo first group.5 All patients crossed over to the alternate intervention at 3 months.5 In 
order to maintain consistency with the other studies being evaluated only the first arm of the 
crossover trial will be evaluated.  
The FMT first group ingested 25 oral capsules each containing 0.38g of single donor 
stool on 3 consecutive days for a total of 75 capsules and 28.5g of feces.5 The placebo group 
ingested placebo capsules of nontoxic brown pigment to mimic the FMT capsules.5 Both were 
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administered with PPI to prevent lysis in the upper GI tract.5 Participants were surveyed at 
baseline, 1, 4, 12, 13 , 16 and 24 weeks after dosing via IBS-SSS and fecal samples were 
collected at each time.5 At baseline, the FMT first group’s IBS-SSS scores were 282 ± 65 and the 
placebo first group’s scores were 309 ± 64, (p=0.15).5 At 3 months the FMT first group’s scores 
were 221± 105 and the placebo first group’s scores were 236 ± 64 (p=0.65)5 indicating the 
results were not statistically significant and therefore it cannot be concluded that any significant 
difference exists between the two groups. A calculated mean change from baseline for each 
groups revealed a 61 point decrease in symptom severity in the FMT first group and a 73 point 
decrease in the placebo first group as shown in Table 6 below. Additionally, participants 
receiving placebo had a higher clinical response rate (61%) at 12 weeks than the FMT group 
(50%) although not statistically different (p=0.46).5 Overall, 47 adverse events related to the 
study drugs occurred during the 6 months with 23 related to FMT and 23 related to placebo 
although no difference was found between the groups as shown in Table 7 below.5  
Table 6 – Mean (SD) change in IBS-SSS from baseline to 3 months and statistical 
significance data from Aroniadis et al5 








FMT group 282 (65) 221 (105) 61   
    0.65 
 
Placebo group 309 (64) 236 (95) 73 
 
Table 7 – Adverse events reported from Aroniadis et al5 
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pain 
Nausea  Diarrhea  Consti-
pation  












































p-value  >.99 0.68 0.20 0.24 0.44 0.50 >.99 0.36 >.99 >.99 
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DISCUSSION: 
 Some degree of improvement in disease severity was noted in all FMT groups across the 
three studies although this was not always statistically significant and symptom improvement 
was seen among groups receiving placebo as well. While Johnsen et al1 found a statistically 
significant treatment effect in favor of FMT (p=0.049) this effect was small and Halkjær et al3 
found a statistically significant treatment effect (p=0.012) in favor of placebo. Furthermore, 
Johnsen et al1 demonstrated 65% of FMT recipients showed a decrease in IBS-SSS of > 75 
points at 3 months which equates to greater than a 15% reduction in symptoms. However, this 
translates to the remaining 35% of participants experiencing a decrease in symptoms by less than 
15%. Additionally, in Aroniadis et al5, both placebo and FMT groups had similar reductions in 
disease severity, with neither reaching more than a 15% reduction in symptoms. These modest 
improvements in symptoms after FMT likely do not warrant recommending FMT over 
conservative therapies to IBS patients at this time.  
While the three studies demonstrated that FMT was not inherently harmful, numerous 
mild adverse effects were noted in all studies and the risks associated with FMT may limit its 
practical application. With colonoscope delivery there is a risk of bowel perforation and 
intolerance to anesthesia.7 Since IBS is a non-lethal disease the risks associated with an 
intervention should be minimized as much as possible.   
Limitations in all three studies are small sample size, making generalizations to larger 
populations challenging and statistical significance difficult to prove. Halkjær et al3 and 
Aroniadis et al5 recruited participants from European countries while Johnsen et al1 recruited 
patients from the United States creating an opportunity for confounding variables such as diet 
and environment to effect study outcomes as lifestyle factors are known to play a role in IBS. 
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Lastly, a limitation of this review is that IBS-subtype studied and amount and type of 
fecal matter transplanted was not consistent across all three studies making it difficult to 
conclude which IBS subtype(s) would most be effected by FMT, at what appropriate dose, and if 
single or mixed donor stool should be utilized. 
CONCLUSION:  
Findings are inconclusive if FMT is better at reducing IBS disease severity compared to 
placebo. Halkjær et al3 and Aroniadis et al5 did not find that FMT improved disease severity 
compared to placebo while Johnsen et al1 did find statistically significant symptom improvement 
among those who received FMT compared to placebo. However, it is important to note that 
placebo improved symptom severity in all studies as well. Due to both placebo and FMT 
demonstrating minor symptom improvement in all 3 studies, it is reasonable to conclude that 
FMT does not improve symptom severity in IBS patients compared to placebo. Symptom 
improvement of this magnitude could likely be achieved with more conservative measures and 
the data does not support utilizing FMT over current treatment regimens for a modest 
improvement in symptoms. 
Since many individuals with IBS purchase over the counter medications to remedy their 
symptoms it is difficult to quantify the cost burden per patient.4 Studies on the cost effectiveness  
of FMT for IBS treatment have not yet been performed however, studies have shown than using 
FMT via colonoscope for recurrent C. difficile infections is in fact more cost effective than 
traditional antibiotic regimens.7 Thus, additional longitudinal studies in this area to evaluate cost 
effectiveness and continuity of symptom improvement would benefit clinical decision making 
when it comes to using FMT as a treatment for IBS. Additionally, FMT delivered orally via 
capsules tend to be faster, cheaper, and better tolerated.7 Further research into FMT delivered 
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orally may offer safer treatment options if proven to be an effective intervention with additional 
RCTs. Additionally, larger studies with more diverse patient populations will be required before 
any change to current clinical practice should be proposed. All three RCTs recruited sample sizes 
under 90 participants and the participants in the study by Aroniadis et al5 were predominately 
male (64%) when IBS is more commonly diagnosed in females. However, according to the 
Cochrane Library’s CENTRAL trials database, 41 ongoing trials evaluating FMT and IBS have 
been added to the database in the last 2 years, with 9 published in 2020 alone. This confirms this 
is an area of increased interest in the medical community and indicates our knowledge on the 
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